LYMPHOID NEOPLASIA

Ibrutinib-based therapy reinvigorates CD8+ T cells compared to chemoimmunotherapy: immune monitoring from the E1912 trial

Despoina Papazoglou,1 Xin Victoria Wang,2,3 Tait D. Shanafelt,4 Connie E. Lesnick,5 Nikolaos Ioannou,1 Giulia De Rossi,6 Sylvia Herter,7 Marina Bacac,7 Christian Klein,7 Martin S. Tallman,8 Neil E. Kay,5 and Alan G. Ramsay1

1School of Cancer and Pharmaceutical Sciences, Faculty of Life Sciences & Medicine, King’s College London, London, United Kingdom; 2Department of Data Science, Dana-Farber Cancer Institute, Boston, MA; 3Department of Biostatistics, Harvard TH Chan School of Public Health, Boston, MA; 4School of Medicine, Stanford University, Stanford, CA; 5Department of Immunology, Mayo Clinic, Rochester, MN; 6Institute of Ophthalmology, University College London, London, United Kingdom; 7Discovery Oncology, Roche Innovation Center Zürich, Schlieren, Switzerland; and 8Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY

Key Points

• Higher effector T-cell numbers and their rejuvenated cytotoxic function accompanies favorable clinical responses to ibrutinib-rituximab.
• Enhanced CD8+ T-cell lytic synapse activity during ibrutinib-rituximab therapy can be exploited using the bispecific antibody glofitamab.

Introduction

E1912 was the first frontline phase 3 study to compare ibrutinib-based therapy (ibrutinib with rituximab) with the chemoimmunotherapy fludarabine, cyclophosphamide, and rituximab (FCR).1 Long-term follow-up has demonstrated superior progression-free survival (PFS) and overall survival for ibrutinib-rituximab relative to those for FCR.7 Nevertheless, clinical challenges remain, including the current need for continuous therapy, tolerability, and residual and progressive disease. Immunotherapy represents a powerful combination or alternative therapy to tackle resistant disease and deepen responses.1,4 However, T-cell exhaustion is a major barrier for optimal immunotherapy.3,6 Dysfunctionality of T cells is characterized by increased chronic lymphocytic leukemia (CLL)-associated T-cell subsets expressing inhibitory checkpoint molecules.7 Furthermore, helper CD4+ T cells have a tumor-promoting capacity, whereas impaired immune synapse formation contributes to suppressed CD8+ T-cell cytotoxicity.8 Correlative studies have revealed that BTKis reduce abnormally high T-cell numbers and checkpoint receptor expression while reducing malignant B cells.9-13 However, the impact of BTKi therapy on T-cell function has not been fully characterized. Here, we performed longitudinal immunophenotypic and functional analysis of pretreatment and on-treatment (6 and 12 months) peripheral blood samples from patients in the phase 3 E1912 trial comparing ibrutinib-rituximab with fludarabine, cyclophosphamide, and rituximab (FCR). Intriguingly, we report that despite reduced overall T-cell counts; higher numbers of T cells, including effector CD8+ subsets at baseline and at the 6-month time point, associated with no infections; and favorable progression-free survival in the ibrutinib-rituximab arm. Assays demonstrated enhanced anti-CLL T-cell killing function during ibrutinib-rituximab treatment, including a switch from predominantly CD4+ T-cell:CLL immune synapses at baseline to increased CD8+ lytic synapses on-therapy. Conversely, in the FCR arm, higher T-cell numbers correlated with adverse clinical responses and showed no functional improvement. We further demonstrate the potential of exploiting rejuvenated T-cell cytotoxicity during ibrutinib-rituximab treatment, using the bispecific antibody glofitamab, supporting combination immunotherapy approaches.

Study design

Samples from patients with CLL

Viable peripheral blood mononuclear cells at baseline and 6-, 12-, and 18-month time points from the Eastern Cooperative...
Figure 1.

- Immune Subset
  - HR
  - Lower 95
  - Upper 95
  - P-value
  - CD8+ TEM
  - CD4+/CD8+ Ratio
  - TRegs of CD4+ ab
  - PD-1+ CD4+ ab
  - CD8+ Tnaive of CD8+
  - TH2 of CD3+
  - TEM of CD8+
  - CD8+ TCM
  - % PD-L1+ CD19+ ab
  - CD8+ TEMRA ab
  - MRD

- Higher levels associated with no infections
- Higher levels associated with infections

Figure 1.
Oncology Group–American College of Radiology Imaging Network (ECOG-ACRIN)-E1912 Cancer Research Group (supplemental Figure 1, available on the Blood website) were biobanked for longitudinal comparative immune analysis. Supplemental Table 1 summarizes the samples studied (ibrutinib-rituximab, n = 89; FCR, n = 62).

Immune monitoring and functional assays are detailed in supplemental Methods.

All patient samples were obtained after written informed consent, in accordance with the declaration of Helsinki, and approved by the National Research Ethics Committees, ECOG-ACRIN and the National Institutes of Health.

Results and discussion
T-cell monitoring and correlation with PFS, MRD, and infections

We initially investigated the impact of therapy on T cells and explored the association with clinical outcome (Figure 1A). Flow cytometry measured the absolute numbers of naive (CD45RA+/CCR7−), central memory (CD45RA−/CCR7−), effector memory (TEM; CD45RA−/CCR7+), and terminally differentiated effector memory (CD45RA+/CCR7+) subsets in patients at baseline and 6- and 12-month treatment time points (supplemental Table 3). This analysis revealed a reduction in the majority of CD4+ and CD8+ T-cell subsets, including naive and effectors, during ibrutinib-rituximab treatment (Figure 1B; supplemental Figure 2A,C), consistent with T-cell normalization, as previously reported for monotherapy.10,13 Expectedly, we observed a marked decrease of subsets after FCR, with evidence of immune reconstitution at 12 months (Figure 1B; supplemental Figure 2B,D).14 The frequencies of subsets remained relatively stable during ibrutinib-rituximab treatment, whereas FCR caused naive and central memory subsets to contract, whereas TEM expanded (supplemental Figure 2E-F). Both therapies reduced the number of regulatory T cells, T helper 17 (T(H)17), and natural killer (NK) cells compared with those at baseline, but an increased the regulatory T-cell to CD4 ratio after FCR was observed (supplemental Figure 3A-C).15 Strikingly, patients on ibrutinib-rituximab with higher T-cell numbers, including PD-1+ effector CD8+ and PD-1+ subsets, at baseline had longer PFS (Figure 1D,F), suggesting the importance of an existent but exhausted immune response before therapy. Interestingly, higher levels of PD-L1-expressing CLL cells at baseline correlated with favorable PFS (Figure 1D,F; multivariable analysis in supplemental Table 4). Furthermore, an elevated frequency of effector CD8+ T cells at the 6-month ibrutinib-rituximab time point associated with favorable PFS, whereas no association was detectable at 12 months (Figure 1D,F). Conversely, higher T-cell numbers correlated with worse PFS in the FCR arm, whereas increased NK-cell frequency at baseline associated with favorable outcome (supplemental Figure 4A). Consistent with tumor-mediated exhaustion, greater numbers of PD-1+ and PD-L1+ CD8+ T-cell subsets associated with higher measurable residual disease (MRD) during ibrutinib-rituximab treatment (supplemental Figure 5A). In contrast, elevated frequencies of T-cell subsets not expressing checkpoint molecules, including CD8+ terminally differentiated effector memory and NK cells, correlated with low MRD during ibrutinib-rituximab treatment, in keeping with reduced exhaustion. An association between T cells and MRD was less evident in the FCR arm, except for increased checkpoint-expression T cells at 12 months, which correlated with higher MRD (supplemental Figure 5B). Ibrutinib’s inhibition of interleukin-2–inducible T-cell kinase (ITK) enhanced T(H)1 polarization,16,17 but both therapeutic arms reduced T(H)1 and T(H)2 numbers and T(H)1:T(H)2 ratios (supplemental Figure 6A-B). Nevertheless, an increased frequency of T(H)2 and CD4:CD8 ratio (baseline and 6 months) associated with unfavorable PFS and incidence of infection, respectively, during ibrutinib-rituximab treatment (Figure 1F-G). However, increased effector CD8+ T-cell numbers and CD16+ NK cells at 6 months were associated with no infections during ibrutinib-rituximab treatment (Figure 1G). Conversely, increased T cells after FCR correlated with infections (supplemental Figure 4B). In sum, higher CD8+ T-cell numbers at baseline and early on-therapy, associated with favorable clinical responses, whereas PD-1+ and PD-L1+ subsets associated with greater MRD during ibrutinib-rituximab treatment.

Ibrutinib-rituximab promotes CD8+ synapses and immunotherapy-triggered killing function

Next, we characterized the cytolytic function of therapy-reshaped T cells against baseline CLL cells (Figure 2A-B). T cells from both 6- and 12-month ibrutinib-rituximab time points showed enhanced killing function compared with those at pretreatment levels. In contrast, T cells after FCR showed no cytolytic improvement. Notably, patients who experienced grade 3 infections during ibrutinib-rituximab treatment showed lower anti-CLL T-cell cytotoxic function (Figure 2C). Hypothesizing altered T-cell:CLL interactions, we then performed
Figure 2. Ibrutinib-rituximab promotes CD8+ T-cell lytic synapse activity and supports immunotherapy-triggered anti-CLL killing function. (A) Illustration of the autologous cytotoxicity assay using anti-CD3/-CD28-activated T cells (cytolytic T lymphocytes [CTLs]) from B/L, 6M, and 12M time points mixed with target B/L CLL B cells (pulsed with superantigen as a model antigen) with flow-based quantification of T-cell killing function. (B) T-cell-mediated CLL cell death comparing T cells purified from B/L, 6M, and 12M time point samples (n = 30 patients per treatment arm). Data at 6M and 12M were normalized to B/L levels to generate fold change values for each patient. (C) The association between patient’s T-cell killing function (12M ibrutinib-rituximab time point, n = 30) and infection status during ibrutinib-rituximab therapy (no infections vs grade 2 or 3 infections) (Wilcoxon test, P = .01). (D-E) Representative confocal medial optical section and 3-dimensional (3D) volume-rendered images of T-cell:CLL conjugates formed between patient T cells (B/L, 6M, and 12M on-ibrutinib-rituximab [D] or FCR [E]) interacting with autologous B/L CLL B cells (blue, CMAC dyed). Bar charts: quantitative relative recruitment index (RRI) analysis of F-actin polarization (red, rhodamine phalloidin) in T-cell:CLL conjugates (n = 50 patients per treatment arm). (F) Box and violin plots (minimum-maximum) showing the percentage of CD4+ or CD8+ T-cell:CLL conjugates formed from the total T-cell:CLL conjugates in B/L, 6M, and 12M ibrutinib-rituximab time point samples (n = 15 patients). Representative confocal images of CD8+ (white) and CD4+ (green) T-cell conjugates with CLL B cells (blue) at B/L vs on ibrutinib-rituximab therapy. (G) Representative confocal 3D volume-rendered images of granzyme B (GrB; white) expression at CD8+ T-cell synapses, comparing ibrutinib-rituximab and FCR 12M time point samples. (H) Kaplan-Meier curve showing the association between the strength of polarized F-actin CD4+ T-cell:CLL immune synapse interactions in patient B/L samples and their PFS outcomes during ibrutinib-rituximab administration. Median F-actin RRI values were used as a cut-off point to determine weak (<median RRI) vs strong (>median RRI) CD4+ T-cell synapses (n = 52 patients). Patients showing strong CD4+ T-cell:CLL immune synapses at B/L showed significantly adverse PFS (9 progression events per 29 patients) compared with patients showing weak CD4+ T-cell:CLL interactions (1 progression event per 23 patients). (Cox model, P = .01; HR, 9.14; 95% confidence interval, 1.15-72.47). Bar chart: F-actin RRI analysis of CD4+ T-cell:CLL conjugates at B/L and representative 3D volume-rendered confocal images comparing patients.
IBRUTINIB-BASED THERAPY REINVIGORATES CD8+ T CELLS

Ibrutinib is known to reduce PD-1 expression on patient T cells. Here, we detected a reduced frequency of PD-1-expressing T-cell subsets during ibrutinib-rituximab administration as well as PD-L1-expressing T cells except for CD8+ TEM at 6 months (Figure 1D-E; supplemental Figure 8). In contrast, T-cell PD-1/PD-L1 expression was relatively unaffected after FCR. This prompted us to investigate for a checkpoint blockade in our cytotoxicity assay (Figure 2K; supplemental Figure 9). Both ibrutinib-rituximab– and FCR-exposed T cells were insensitive to anti–PD-1. However, anti–PD-L119 increased anti-CLL T-cell cytotoxicity only at the 6-month ibrutinib-rituximab time point, suggesting a narrow window for the checkpoint blockade activity.7 This led us to investigate whether the T-cell–engaging bispecific antibody golfitamab (CD20 × CD3)20 could trigger improved cytolytic responses. T cells from all ibrutinib-rituximab time points tested up to 18 months showed increased anti-CLL T-cell killing after treatment with golfitamab, compared with those at baseline (Figure 2L-N). However, T cells after FCR did not respond to golfitamab, including at the later time point. Overall, these data support the ability of ibrutinib-based therapy to enhance T-cell-mediated cytotoxicity induced by bispecific immunotherapy.

In summary, our data highlight the importance of T cells during ibrutinib-rituximab therapy, with higher T-cell numbers and rejuvenated cytotoxicity accompanying favorable clinical responses. Our exploratory findings that increased levels of PD-1–expressing T cells as well as PD-L1–expressing CLL cells...
before therapy associate with longer PFS suggests that ibrutinib-rituximab appears to capitalize on T-cell–mediated immune surveillance in patients. Strikingly, opposing associations were found in the chemoimmunotherapy arm, and T cells showed no functional improvement after FCR. Previous studies have reported CD8+ T clonotype expansion during ibrutinib therapy, likely reflecting active immunosurveillance. Taken together, tumor debulking and alleviation of T-cell exhaustion during BTKi-based therapy may promote CD8+ T-cell activity. The switch from CD4+ T-cell:CLL interactions at baseline to CD8+ lytic synapses during ibrutinib-rituximab therapy supports this concept. Although ibrutinib-rituximab did not increase TIL numbers, we do not exclude ITK inhibition contributing to beneficial immunomodulation. Furthermore, our longitudinal assays designed to evaluate changes in T-cell cytolytic function with therapy, revealed that revitalized cytotoxicity during ibrutinib-rituximab therapy could be maximized with golfitamab, further supporting combination immunotherapy approaches. Overall, this report underscores the importance of trial-associated science to understand how BTKIs modulate T cells and supports the development of immunotherapy-based therapies.

Acknowledgments

The authors thank the Nikon Imaging Facility at King’s College London. This study was coordinated, in part, by the ECOG-ACRIN Cancer Research Group (Peter J. O’Dwyer and Mitchell D. Schnall, joint group chairs).

This study was supported by the National Institutes of Health, National Cancer Institute awards RO1CA193541, U10CA180820, UG1CA232760, UG1CA233290, U10CA180794, and RO1CA251801.

The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

REFERENCES


17. Sagiv-Barf I, Kohut HE, Czewniski DK, Ng PP, Chang BY, Levy R. Therapeutic antitumor immunity by checkpoint blockade is

Authorship

Contribution: D.P. designed, performed experimental work, analyzed data, and wrote the manuscript; X.W.V. performed data and association analysis; C.E.L. and N.I. performed experimental work; G.D.R. contributed to image analysis; T.D.S., N.E.K., and M.S.T. designed and supervised the study and managed data; S.H., M.B., and C.K. provided the bispecific antibodies and advised on the study; A.G.R. designed and supervised the study and wrote the manuscript.

Conflict-of-interest disclosure: S.H., M.B., and C.K. are employees of and declare patents and stock ownership with Roche Glycart AG. A.G.R. has received research support from Roche Glycart AG to Institution as part of a research collaboration. The remaining authors declare no competing financial interests.

ORCID profiles: D.P., 0009-0008-5818-8663; G.D.R., 0000-0001-6163-4590; N.E.K., 0000-0002-5951-5055; A.G.R., 0000-0002-0452-0420.

Correspondence: Alan G. Ramsay, Lymphoma Immunology, Innovation Hub, Guy’s Cancer Centre, Great Maze Pond, London SE1 9RT, United Kingdom; email: alan.ramsay@kcl.ac.uk.

Footnotes


Presented in abstract form at the 60th annual meeting of the American Society of Hematology, San Diego, CA, 1 to 4 December 2018.

Original data and protocols are available on request from the corresponding author, Alan G. Ramsay (alan.ramsay@kcl.ac.uk).

The online version of this article contains a data supplement.

There is a Blood Commentary on this article in this issue.

The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked “advertisement” in accordance with 18 USC section 1734.
enhanced by ibrutinib, an inhibitor of both BTK and ITK. *Proc Natl Acad Sci U S A.* 2015;112(9):E966-E972.


